• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 4. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

Professional Introduction to 1-(Piperidin-4-yl)cyclopropan-1-ol (CAS No. 1358782-67-8)

1-(Piperidin-4-yl)cyclopropan-1-ol (CAS No. 1358782-67-8) is a significant compound in the field of pharmaceutical chemistry, exhibiting a unique structural framework that has garnered considerable attention from researchers worldwide. This compound, characterized by its cyclopropane ring fused with a piperidine moiety, presents an intriguing chemical profile that makes it a valuable candidate for further exploration in drug discovery and development.

The structural motif of 1-(Piperidin-4-yl)cyclopropan-1-ol combines the rigidity of the cyclopropane ring with the versatility of the piperidine nitrogen-containing heterocycle. The cyclopropane ring is known for its high reactivity and strain, which can be leveraged to modulate biological activity. Meanwhile, the piperidine moiety is a common pharmacophore in medicinal chemistry, often found in drugs targeting neurological and cardiovascular diseases due to its ability to enhance binding affinity and metabolic stability.

In recent years, there has been a surge in research focused on developing novel compounds with hybrid structures like 1-(Piperidin-4-yl)cyclopropan-1-ol. The combination of these two structural elements offers a promising avenue for creating molecules with enhanced pharmacological properties. For instance, studies have shown that cyclopropane derivatives can exhibit potent inhibitory effects on various enzymes and receptors, while piperidine-based compounds are frequently employed in the design of central nervous system (CNS) therapeutics.

One of the most compelling aspects of 1-(Piperidin-4-yl)cyclopropan-1-ol is its potential as a building block for more complex drug candidates. The presence of both the cyclopropane and piperidine groups provides multiple sites for functionalization, allowing chemists to tailor the molecule's properties to specific biological targets. This flexibility has led to several innovative synthetic strategies being developed to access derivatives of this compound with tailored pharmacokinetic profiles.

The pharmacological potential of 1-(Piperidin-4-yl)cyclopropan-1-ol has been explored in various preclinical studies. Researchers have investigated its interactions with enzymes such as cytochrome P450 monooxygenases and ATP-binding cassette transporters, which are critical for drug metabolism and efflux. Preliminary findings suggest that this compound may exhibit inhibitory effects on these targets, potentially leading to applications in treating metabolic disorders and multidrug resistance.

In addition to its enzymatic interactions, 1-(Piperidin-4-yl)cyclopropan-1-ol has shown promise in binding studies with neurological receptors. Piperidine-based compounds are well-known for their ability to interact with serotonin and dopamine receptors, making them valuable candidates for treating conditions such as depression and Parkinson's disease. The incorporation of the cyclopropane ring into this framework may further enhance binding affinity and selectivity, opening new possibilities for CNS drug development.

The synthesis of 1-(Piperidin-4-yl)cyclopropan-1-ol has been optimized through several methodologies, each offering distinct advantages in terms of yield, purity, and scalability. One common approach involves the reaction of piperidine derivatives with cyclopropyl halides under palladium-catalyzed conditions. This method leverages cross-coupling reactions to form the desired bond between the piperidine nitrogen and the cyclopropane carbon, providing a robust synthetic route.

Another innovative synthetic strategy involves the use of organometallic reagents to construct the cyclopropane ring directly from acyclic precursors. These methods often employ zinc or copper catalysts to facilitate ring closure, offering high atom economy and minimal byproduct formation. Such advances in synthetic chemistry have made it increasingly feasible to produce complex molecules like 1-(Piperidin-4-yl)cyclopropan-1-ol on a larger scale, facilitating further pharmacological investigation.

The computational modeling of 1-(Piperidin-4-yl)cyclopropan-1-ol has also played a crucial role in understanding its potential biological activity. Molecular dynamics simulations and quantum mechanical calculations have been used to predict how this compound interacts with biological targets at an atomic level. These studies provide valuable insights into its binding mode and affinity, guiding the design of more effective derivatives.

In conclusion, 1-(Piperidin-4-y lcyc lo pro pan - 1 - ol

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)